Vertaling van "stuart " (Engels → Frans) :

TERMINOLOGIE

Stuart factor [ Stuart-Prower factor | factor X | FX | coagulation factor X | autoprothrombin C | Prower factor ]
facteur Stuart [ facteur X ]

STUART-BRAS syndrome
syndrome de STUART-BRAS-JELLIFFE

Stuart transport medium
milieu de Stuart pour transport de germes

Stuart-Prower factor
facteur Stuart-Prower | facteur X

Bengough-Stuart process
procédé Bengough-Stuart

factor X | Stuart-Prower factor | prothrombinase | Stuart factor
facteur X | facteur Stuart | facteur Stuart-Prower-Delia

Congenital afibrinogenaemia Deficiency:AC globulin | proaccelerin | Deficiency of factor:I [fibrinogen] | II [prothrombin] | V [labile] | VII [stable] | X [Stuart-Prower] | XII [Hageman] | XIII [fibrin-stabilizing] | Dysfibrinogenaemia (congenital) Hypoproconvertinaemia Owren's disease
Afibrinogénémie congénitale Carence en:AC-globuline | proaccélérine | Carence en facteur:I [fibrinogène] | II [prothrombine] | V [labile] | VII [stable] | X [Stuart-Prower] | XII [Hageman] | XIII [stabilisant de la fibrine] | Disfibrinogénémie (congénitale) Hypoproconvertinémie Maladie de Owren

Collected Works of John Stuart Mill
Collected Works of John Stuart Mill

IN-CONTEXT TRANSLATIONS

IMCO Committee: Stuart Agnew to replace Margot Parker
commission IMCO: Stuart Agnew à la place de Margot Parker

Appellant: Asos plc (represented by: P. Kavanagh, Solicitor, A. Lykiardopoulos QC, A. Edwards-Stuart, Barrister)
Partie requérante: Asos plc (représentants: P. Kavanagh, solicitor, A.Lykiardopoulos, QC, et A. Edwards-Stuart, barrister)

Bolin, B., R. Garman, K. Jensen, G. Krinke, B. Stuart, and an ad Hoc Working Group of the STP Scientific and Regulatory Policy Committee (2006), “A “Best Practices” Approach to Neuropathologic Assessment in Developmental Neurotoxicity Testing — for Today”, Toxicological Pathology, 34, 296-313.
Bolin, B., Garman, R., Jensen, K., Krinke, G., Stuart, B., and an ad Hoc Working Group of the STP Scientific and Regulatory Policy Committee (2006), “A 'Best Practices' Approach to Neuropathologic Assessment in Developmental Neurotoxicity Testing — for Today”, Toxicological Pathology, 34, 296-313.

Bolon, B., Garman, R., Jensen, K., Krinke, G., Stuart, B., and an ad hoc working group of the STP Scientific and Regulatory Policy Committee (2006) A “best practices” approach to neuropathological assessment in developmental neurotoxicity testing — for today. Toxicol.
Bolon, B., Garman, R., Jensen, K., Krinke, G., Stuart, B., and an ad hoc working group of the STP Scientific and Regulatory Policy Committee (2006), A 'best practices' approach to neuropathological assessment in developmental neurotoxicity testing — for today, Toxicol.

In order to arrive at a reliable estimate of the variability around the mean it is necessary to refer to the robust standard deviation as estimated according to Stuart and Kendall (4).
Pour obtenir une estimation fiable de la variabilité autour de la moyenne, il convient de se référer à l’estimation de l’écart type robuste selon Stuart et Kendall (4).

John Stuart Agnew, on behalf of the EFD Group.
John Stuart Agnew, au nom du groupe EFD.

John Stuart Agnew and David Campbell Bannerman (EFD), in writing.
John Stuart Agnew et David Campbell Bannerman (EFD), par écrit.

John Stuart Agnew (EFD), in writing.
John Stuart Agnew (EFD), par écrit.

Sometimes, when discussing climate change, I remember what John Stuart Mill said about his father.
Parfois, lorsqu’il discutait du changement climatique, je me souviens de ce que John Stuart Mill disait à propos de son père.

To obtain a reliable estimate of the variability that arises around the median, recourse is required to the Stuart and Kendall method of estimating the robust standard deviation.
Pour obtenir une estimation fiable de la variabilité qui se produit autour de la médiane, il faut se reporter à l'estimation de l'écart type robuste d'après Stuart et Kendall.